OREXIGEN™ Therapeutics, Inc. is a biopharmaceutical company focused on
the development and commercialization of pharmaceutical products for
the treatment of central nervous system disorders, with an initial
focus on obesity. OREXIGEN’s lead combination product candidates
targeted for obesity are Contrave™, which is in a Phase III clinical
trial, and Empatic™ (formerly Excalia™), which is in a Phase IIb
clinical trial.
more
Founders:
Also known as:
- Orexigen